Alternative Data for vTv Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 96 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,734 | Sign up | Sign up | Sign up |
| X Followers | 363 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
About vTv Therapeutics
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs.
| Price | $35.02 |
| Target Price | Sign up |
| Volume | 58,375 |
| Market Cap | $139M |
| Year Range | $14 - $42.72 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10 - GlobeNewswire |
|
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737March 3 - Yahoo Entertainment |
|
vTv Therapeutics to Participate in Upcoming Investor ConferencesFebruary 13 - GlobeNewswire |
|
 |
This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayJanuary 5 - Biztoc.com |
 |
vTv Therapeutics initiated with bullish view at TD Cowen, here's whyJanuary 5 - Thefly.com |
 |
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next CatalystFebruary 27 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -8.7M | -10M | -1.080 |
| Q2 '25 | 0 | 3,000 | -3,000 | -6M | -7.7M | -0.920 |
| Q1 '25 | 0 | 9,000 | -9,000 | -5.1M | -6.5M | -0.770 |
| Q4 '24 | 17,000 | 22,000 | -5,000 | -3.6M | -4.4M | -0.552 |
| Q3 '24 | 0 | 22,000 | -22,000 | -4.8M | -5.8M | -0.877 |
Insider Transactions View All
| SEKHRI PAUL J filed to buy 5,000 shares at $17. November 19 '24 |
| SEKHRI PAUL J filed to buy 1,378 shares at $16.4. November 19 '24 |
| SEKHRI PAUL J filed to buy 3,156 shares at $16.9. November 19 '24 |
| FRY JOHN A filed to buy 61,000 shares at $0.8. November 30 '22 |
| FRY JOHN A filed to buy 20,539 shares at $0.8. November 30 '22 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$243.71 0.5% | 57 |
 |
Eli Lilly and CompanyLLY |
$1001.35 0.7% | 62 |
 |
PfizerPFE |
$27.16 1.3% | 30 |
 |
AstrazenecaAZN |
$194.99 0% | 57 |
 |
AbbVieABBV |
$227.01 0.2% | 72 |
Read more about vTv Therapeutics (VTVT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & business outlook.
FAQ - vTv Therapeutics
The Market Cap of vTv Therapeutics is $139M.
Currently, the price of one share of vTv Therapeutics stock is $35.02.
The VTVT stock price chart above provides a comprehensive visual representation of vTv Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling vTv Therapeutics shares. Our platform offers an up-to-date VTVT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, vTv Therapeutics (VTVT) does not offer dividends to its shareholders. Investors interested in vTv Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of vTv Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
